PMID- 33045753 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20210921 IS - 1439-0795 (Electronic) IS - 0176-3679 (Linking) VI - 54 IP - 1 DP - 2021 Jan TI - Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission. PG - 23-30 LID - 10.1055/a-1252-2942 [doi] AB - INTRODUCTION: In a previous report, we used canonical correlation analysis to classify individuals with clinical high risk (CHR) of psychosis into the 3 subtypes: subtype-1, characterized by extensive negative symptoms and cognitive deficits, appeared to have the highest risk for conversion to psychosis; subtype-2, characterized by thought and behavioral disorganization, with moderate cognitive impairment; subtype-3, characterized by the mildest symptoms and cognitive deficits. The present study attempted to identify these subtypes' response to antipsychotic (AP) treatment. METHODS: A total of 289 individuals with CHR were identified and followed up for 2 years. Individuals with CHR were classified by subtype. Use of APs was examined at 2-month, 1-year, and 2-year follow-up interviews that inquired after the subjects' medication history since the first visit. The main outcome was remission, determined according to global assessment of function (GAF) score (i. e., functional outcome) and SIPS positive symptom score (symptomatic outcome) at the follow-up points. RESULTS: Among the 289 individuals with CHR included in the current analysis, 223 (77.2%) were treated using APs for at least 2 weeks during the follow-up period. Individuals with CHR tended to show significant improvement in both symptoms and function after 2 years, but subtypes exhibited significantly different trajectories. Subtype status can predict AP treatment outcome in terms of remission. The likelihood of remission differed significantly among the subtype groups. The remission rates for individuals with subtypes 1-3 treated using AP were 13.5%, 36.1%, and 67.0%, respectively. DISCUSSION: These subtypes may be of clinical value in AP treatment decision-making in the CHR population. CI - Thieme. All rights reserved. FAU - Zhang, TianHong AU - Zhang T AUID- ORCID: 0000-0002-5379-7119 AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Wang, JunJie AU - Wang J AD - Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou. FAU - Xu, LiHua AU - Xu L AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Wei, YanYan AU - Wei Y AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Tang, XiaoChen AU - Tang X AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Hu, YeGang AU - Hu Y AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Cui, HuiRu AU - Cui H AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Tang, YingYing AU - Tang Y AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Hui, Li AU - Hui L AD - Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou. FAU - Li, ChunBo AU - Li C AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. FAU - Wang, JiJun AU - Wang J AD - Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai. AD - Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai. AD - Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai. LA - eng GR - Ministry of Science and Technology of China, National Key R&D Program of China/2016YFC1306800/ GR - National Natural Science Foundation of China/81671329/ GR - National Natural Science Foundation of China/81671332/ GR - National Natural Science Foundation of China/81901832/ GR - Shanghai Key Laboratory of Psychotic Disorders/13dz2260500/ GR - Science and Technology Commission of Shanghai Municipality/No.2018SHZDZX01/ GR - Science and Technology Commission of Shanghai Municipality/19ZR1477800/ GR - Science and Technology Commission of Shanghai Municipality/19ZR1445200/ GR - Science and Technology Commission of Shanghai Municipality/19441907800/ GR - Science and Technology Commission of Shanghai Municipality/17411953100/ GR - Science and Technology Commission of Shanghai Municipality/19410710800/ GR - Science and Technology Commission of Shanghai Municipality/19411969100/ GR - Science and Technology Commission of Shanghai Municipality/20ZR1448600/ GR - Shanghai Clinical Research Center for Mental Health/19MC1911100/ GR - Clinical Research Center at Shanghai Mental Health Center/CRC2018ZD01/ GR - Clinical Research Center at Shanghai Mental Health Center/CRC2018ZD04/ GR - Clinical Research Center at Shanghai Mental Health Center/CRC2018YB01/ PT - Journal Article PT - Observational Study DEP - 20201012 PL - Germany TA - Pharmacopsychiatry JT - Pharmacopsychiatry JID - 8402938 RN - 0 (Antipsychotic Agents) SB - IM MH - Adult MH - Antipsychotic Agents/*therapeutic use MH - China MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Psychiatric Status Rating Scales MH - Psychotic Disorders/*classification/*drug therapy MH - Remission Induction MH - Risk Factors MH - Severity of Illness Index COIS- The authors declare that they have no conflict of interest. EDAT- 2020/10/13 06:00 MHDA- 2021/09/22 06:00 CRDT- 2020/10/12 20:16 PHST- 2020/10/13 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] PHST- 2020/10/12 20:16 [entrez] AID - 10.1055/a-1252-2942 [doi] PST - ppublish SO - Pharmacopsychiatry. 2021 Jan;54(1):23-30. doi: 10.1055/a-1252-2942. Epub 2020 Oct 12.